← Back to the fund page Use your browser's print dialog and choose “Save as PDF”. A4, two pages.
InvestVerdict

Mahindra Manulife Aggressive Hybrid Fund

Regular Plan · Growth · Aggressive Hybrid · Scheme code 147447

NAV₹27.2041as on 28 Aug 2026
Fund houseMahindra Manulife Mutual Fund
CategoryAggressive Hybrid
Plan & optionRegular · Growth
History7.1 years

Returns (%)

 1M3M6M1Y3Y5Y7Y10YLaunch
This scheme 0.924.23-0.23 1.0211.7111.01 15.24—15.14
Nifty 100
benchmark		 0.253.49-1.52 1.8410.529.38 ——12.79
Aggressive Hybrid
category median		 ——— 2.8111.289.74 —11.80—

Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published NAV history for this scheme.

Risk

 VolatilitySharpeSortinoBetaAlphaMax fallR²
This scheme 12.1% 0.43 0.58 0.74 3.37% -25.5% 93.67
Nifty 100
benchmark		 17.1%0.23 0.32—— -37.0%—

Risk-free rate 6.5%. Beta, alpha and R² are regressed on the 82 months this scheme and its benchmark share.

Growth of ₹100 since launch

721462212962020202220242026InvestVerdict

Drawdown from peak (%)

0%-9%-17%-26%2020202220242026

Every one-year period it has lived through

WindowsWorstMedianBestPeriods that lost money
302 -5.2% 13.5% 59.2% 7%

Every one-year holding period in this scheme's history, not just the last one — the spread a real investor would have met depending only on when they started.

InvestVerdict

Mahindra Manulife Aggressive Hybrid Fund

Regular Plan · Growth

Allocation

By asset

Equity74.17%
Debt18.85%
Cash & Equivalents5.30%
REITs / InvITs2.40%

By market cap

Concentration

Number of stocks103
Top 5 stocks18.11%
Top 10 stocks28.01%
Top 20 stocks42.61%
Largest holding5.73%
Largest sectorBanks 18.48%
Effective stocks63.3
Cash5.30%
InvestVerdict

Mahindra Manulife Aggressive Hybrid Fund

Regular Plan · Growth · holdings

Sector split

Banks — 18.5%Finance — 5.9%CRISIL A1+ — 5.7%Cash & Equivalents — 5.3%Pharmaceuticals & Biotechnology — 4.4%Retailing — 4.3%CRISIL AAA — 4.0%Consumer Durables — 3.8%SOVEREIGN — 3.7%Other — 45.1%Banks18.5%Finance5.9%CRISIL A1+5.7%Cash & Equivalents5.3%Pharmaceuticals & Biotech…4.4%Retailing4.3%CRISIL AAA4.0%Consumer Durables3.8%SOVEREIGN3.7%Other45.1%
Banks18.48%
Finance5.90%
CRISIL A1+5.67%
Cash & Equivalents5.30%
Pharmaceuticals & Biotechnology4.43%
Retailing4.31%
CRISIL AAA4.01%
Consumer Durables3.77%
SOVEREIGN3.71%
Industrial Products3.60%

A ₹10,000 monthly SIP over five years

InvestedValueGainXIRR
₹600,000 ₹778,691 ₹178,691 10.37%

XIRR, not CAGR — a SIP's money arrives over sixty months, so each instalment has been invested for a different length of time.

Not investment advice. InvestVerdict is not a SEBI-registered Investment Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past returns do not predict future ones. Generated 1 Sep 2026.